What is ARCALYST and what conditions does it treat?

ARCALYST (rilonacept) Injection for Subcutaneous Use is an interleukin-1 blocker approved by the FDA for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), specifically Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 years of age and older.

What is the significance of this FDA approval for Regeneron?

This FDA approval is a major event for Regeneron as it represents the first marketing approval for ARCALYST, moving a key drug candidate from development to commercialization. It validates the company's R&D capabilities and opens a new revenue stream.

What does 'interleukin-1 blocker' mean in the context of ARCALYST?

An interleukin-1 blocker, like ARCALYST, works by inhibiting the activity of interleukin-1, a protein that plays a key role in causing inflammation in the body. By blocking this protein, ARCALYST helps to reduce the symptoms associated with inflammatory conditions like CAPS.

When was this approval officially announced?

Regeneron Pharmaceuticals, Inc. issued a press release announcing the FDA approval on February 27, 2008, which was subsequently filed in this Form 8-K report.

REGN 8-K SEC Disclosure

Summary

Regeneron Pharmaceuticals, Inc. (REGN) announced a significant milestone in its Form 8-K filing dated February 28, 2008, reporting that on February 27, 2008, the company received marketing approval from the U.S. Food and Drug Administration (FDA) for ARCALYST™ (rilonacept) Injection for Subcutaneous Use. This approval marks the first indication for ARCALYST, positioning it as a treatment for Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in patients aged 12 and older. This FDA approval is a crucial development for Regeneron, signifying the successful transition of a key pipeline asset to commercialization. Investors should view this as a validation of the company's research and development efforts and a potential driver of future revenue growth. The approval for ARCALYST addresses a significant unmet need in rare autoinflammatory diseases, potentially establishing Regeneron as a leader in this therapeutic area.

Key Highlights

1FDA marketing approval granted for ARCALYST™ (rilonacept) Injection for Subcutaneous Use.
2ARCALYST is approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS).
3Target patient population includes adults and children aged 12 and older with FCAS and MWS.
4This approval represents a significant commercialization milestone for Regeneron.
5The drug is an interleukin-1 blocker, targeting specific inflammatory pathways.
6This event was officially announced via a press release on February 27, 2008.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Feb 29, 2008)

Summary

Key Highlights

Frequently Asked Questions